Discovery of the selective sphingomyelin synthase 2 inhibitors with the novel structure of oxazolopyridine was written by Qi, Xiang-Yu;Cao, Yang;Li, Ya-Li;Mo, Ming-Guang;Zhou, Lu;Ye, De-Yong. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2017.Recommanded Product: 2-(Bromomethyl)-1,3-dimethylbenzene This article mentions the following:
Sphingomyelin synthase (SMS) is a key enzyme in sphingomyelin biosynthetic pathway, whose activity is highly related to the atherosclerosis progression. SMS2 could serve as a promising therapeutic target for atherosclerosis. Based on the structure of lead compound I, a series of oxazolopyridine derivatives were designed, synthesized, and their inhibitory activities against purified SMS1 and SMS2 enzymes were evaluated, resp. The representative mols. 2-(2-((3-chlorobenzyl)oxy)phenyl)oxazolo[5,4-b]pyridine and 2-(2-((3-methoxybenzyl)oxy)phenyl)oxazolo[5,4-b]pyridine possess micromolar inhibitory activities against SMS2 and excellent isoform preferences over SMS1, qualified to be selected as potential mols. in further discovery of specific SMS2 inhibitors. In the experiment, the researchers used many compounds, for example, 2-(Bromomethyl)-1,3-dimethylbenzene (cas: 83902-02-7Recommanded Product: 2-(Bromomethyl)-1,3-dimethylbenzene).
2-(Bromomethyl)-1,3-dimethylbenzene (cas: 83902-02-7) belongs to organobromine compounds. Many of the organo bromine compounds are relatively nonpolar. Bromine is more electronegative than carbon (2.8 vs 2.5) and hence the carbon in a carbon–bromine bond is electrophilic in nature. In the pharmaceutical industry organo bromine derivatives are used as sedatives, vasodilators, antiseptic agents, and anticancer agents.Recommanded Product: 2-(Bromomethyl)-1,3-dimethylbenzene
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary